Hermetica Superfood Encyclopedia
The Short Answer
Chromium dinicotinate glycinate delivers trivalent chromium (Cr³⁺) chelated to niacin and glycine, enhancing insulin receptor signaling, promoting GLUT4-mediated glucose uptake, and reducing pro-inflammatory cytokines including TNF-α, IL-6, and CRP. In a controlled rat model of diabetes, the closely related chromium niacinate form (400 µg Cr/day) significantly reduced HbA1c, triglycerides, cholesterol, and lipid peroxidation versus diabetic controls (p < 0.05 for each outcome), outperforming chromium picolinate on multiple inflammatory and metabolic endpoints.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordchromium dinicotinate glycinate benefits
Chromium Dinicotinate Glycinate — botanical close-up
Health Benefits
**Insulin Sensitivity Enhancement**
Trivalent chromium facilitates insulin binding to its receptor and amplifies downstream phosphorylation cascades, increasing GLUT4 transporter translocation to cell membranes and thereby improving cellular glucose uptake in insulin-resistant tissues.
**Glycemic Control Support**
Supplementation with niacinate forms of chromium has been associated with reductions in HbA1c and fasting glucose in animal models of type 2 diabetes, with human chromium trials showing benefit particularly in individuals with frank chromium deficiency or poor glycemic control.
**Lipid Profile Improvement**
Chromium niacinate at 400 µg Cr/day significantly reduced serum triglycerides (p=0.04) and total cholesterol (p=0.04) in diabetic rats compared to untreated diabetic controls, suggesting a role in broader cardiometabolic risk reduction.
**Anti-Inflammatory Action**
The chelate suppresses pro-inflammatory cytokines TNF-α (p=0.04), IL-6 (p=0.02), and CRP (p=0.02) in diabetic animal models, likely through improved insulin signaling that attenuates NF-κB-mediated inflammatory gene transcription.
**Oxidative Stress Reduction**
Chromium niacinate reduced lipid peroxidation markers (p=0.01) in diabetic rats, indicating antioxidant activity potentially mediated through upregulation of endogenous antioxidant enzymes and reduced mitochondrial reactive oxygen species generation secondary to improved glucose utilization.
**Blood Pressure Modulation**
In hypertensive animal models, chromium nicotinate forms have demonstrated attenuation of sucrose-induced blood pressure elevations, an effect attributed to combined antioxidant activity and improved insulin-mediated vascular function.
**Favorable Safety Versus Picolinate**
Unlike chromium picolinate, which carries documented concerns regarding chromosomal damage and potential genotoxicity in cell models, the nicotinate-glycinate chelate form shows no hematological adverse signals in animal studies and is generally regarded as the preferred form for safety-sensitive populations.
Origin & History
Natural habitat
Chromium dinicotinate glycinate is a wholly synthetic chelate compound with no geographic or botanical origin; it is manufactured through industrial chemical synthesis by coordinating trivalent chromium (Cr³⁺) with niacin (nicotinic acid) and the amino acid glycine as stabilizing ligands. The resulting chelate, sometimes described by the approximate formula C₁₈H₁₂CrN₃O₆ for related chromium(III) nicotinate forms, is produced as a stable powder intended for encapsulation or tableting. Commercial production emerged primarily in the 1990s as formulators sought safer and more bioavailable alternatives to chromium picolinate for use in nutritional supplements and medical foods targeting glucose and insulin metabolism.
“Chromium has no history of use in any traditional herbal or ethnopharmacological medicine system; its biological essentiality was first identified in the 1950s when Walter Mertz and colleagues at the USDA demonstrated that a chromium-containing "glucose tolerance factor" (GTF) isolated from brewer's yeast could restore impaired glucose tolerance in rats. The concept of niacin-bound chromium as a supplement emerged in the late 1980s and early 1990s, driven largely by academic and commercial interest in developing nutritional interventions for the growing epidemic of type 2 diabetes and insulin resistance in Western populations. Chromium dinicotinate glycinate as a specific dual-ligand chelate represents a more recent formulation innovation intended to combine the proposed bioavailability advantages of niacin coordination with the amino acid stabilization provided by glycine, distinguishing it from both the earlier GTF extracts and the widely studied but safety-questioned chromium picolinate. Unlike botanicals with centuries of documented use, the entire history of this compound spans fewer than four decades and is rooted in nutritional biochemistry research rather than cultural or traditional healing practice.”Traditional Medicine
Scientific Research
The current evidence base for chromium dinicotinate glycinate specifically is very limited, with no published large-scale randomized controlled trials (RCTs) identified for this precise chelate form; the most directly relevant controlled data derive from small animal studies using the closely related chromium niacinate form, including one rat study (n=5–6 per group) demonstrating statistically significant improvements in HbA1c, inflammatory cytokines, lipid peroxidation, and lipid panel versus untreated diabetic controls. Broader human clinical evidence on chromium supplementation (various forms) shows inconsistent results: some RCTs in type 2 diabetes patients report modest improvements in fasting glucose and insulin sensitivity, particularly in chromium-deficient individuals, while several systematic reviews and meta-analyses of chromium picolinate and polynicotinate conclude that effect sizes are modest and clinical relevance uncertain. A key methodological limitation across the field is that most positive human trials were conducted in populations with likely baseline chromium insufficiency, making extrapolation to replete individuals problematic; no head-to-head RCT comparing chromium dinicotinate glycinate to other chelate forms in humans has been published. Overall, the evidence tier remains preliminary-to-moderate, and definitive efficacy conclusions for this specific chelate await adequately powered, placebo-controlled human trials with standardized dosing and verified chromium status at baseline.
Preparation & Dosage
Traditional preparation
**Capsules/Tablets (most common form)**
Chromium dinicotinate glycinate chelate powder encapsulated or compressed; standard supplemental doses range from 200–1,000 µg elemental chromium per day, with 200–400 µg/day as the most commonly used range for metabolic support.
**Powder for blending**
Used in combination glucose-support formulas; elemental chromium content must be specified on the label as the chelate mass is substantially greater than elemental Cr content.
**Standardization**
No universal pharmacopoeial standardization exists; reputable products specify elemental chromium content (µg) per dose and confirm trivalent (Cr³⁺) form; independent third-party testing (e.g., NSF, USP) is advisable.
**Timing**
Best taken with meals to coincide with postprandial insulin release and minimize gastrointestinal discomfort; splitting daily doses across 2–3 meals may improve tolerability and maintain steadier tissue delivery.
**Animal study equivalent dose**
400 µg Cr/day used in rat efficacy models; human equivalent doses require allometric scaling and should be determined with practitioner guidance.
**Upper limit reference**
The US Institute of Medicine has not established a Tolerable Upper Intake Level (UL) for trivalent chromium due to low toxicity, but most authorities caution against exceeding 1,000 µg elemental Cr/day from supplements without medical supervision.
Nutritional Profile
Chromium dinicotinate glycinate contributes no macronutrients (protein, fat, carbohydrate) or caloric value at supplemental doses. The elemental chromium content is the sole nutritionally active component, typically delivered at 200–400 µg per dose, which is well above the US Adequate Intake (AI) for chromium (20–35 µg/day for adults) but within the range studied in metabolic research. The niacin (nicotinic acid) and glycine ligands are present in trace amounts relative to full nutritional doses of these compounds and do not meaningfully contribute to niacin or amino acid status at standard supplemental doses. Bioavailability of chromium from chelated forms is generally regarded as superior to inorganic chromium chloride (estimated absorption 0.4–2% for inorganic forms), with chelation protecting Cr³⁺ from alkaline precipitation in the small intestine; however, head-to-head human absorption studies for dinicotinate glycinate versus other forms remain limited.
How It Works
Mechanism of Action
Trivalent chromium (Cr³⁺) potentiates insulin receptor tyrosine kinase activity by binding to a low-molecular-weight chromium-binding protein (LMWCr, also called chromodulin), which activates the insulin receptor and amplifies intracellular signaling through the PI3K/Akt pathway, ultimately driving GLUT4 vesicle translocation to the plasma membrane and enhanced glucose influx into skeletal muscle and adipose cells. Chelation with niacin and glycine protects the Cr³⁺ ion from premature hydrolysis and precipitation in the gastrointestinal environment, increasing mucosal absorption relative to inorganic chromium salts and delivering more bioavailable chromium to target tissues. The improved insulin signaling downstream reduces compensatory hyperinsulinemia, which in turn attenuates NF-κB activation and the transcription of pro-inflammatory cytokines (TNF-α, IL-6) and acute-phase proteins (CRP), while concurrently lowering mitochondrial oxidative stress and lipid peroxidation through more efficient glucose oxidation. At the lipid metabolism level, enhanced insulin sensitivity reduces hepatic de novo lipogenesis and promotes lipoprotein lipase activity, contributing to the observed reductions in circulating triglycerides and total cholesterol.
Clinical Evidence
The most controlled data available involve a rat model of streptozotocin-induced diabetes in which chromium niacinate (400 µg elemental Cr/day, n=5) reduced TNF-α, IL-6, CRP, lipid peroxidation, HbA1c, triglycerides, and cholesterol relative to diabetic controls (n=6), with p-values ranging from 0.01 to 0.04; chromium niacinate outperformed chromium picolinate on the majority of these endpoints, but effect sizes were not reported as standardized metrics (e.g., Cohen's d), and the sample sizes are too small for clinical extrapolation. Human trials examining chromium broadly (picolinate and polynicotinate forms at 200–1,000 µg/day) have shown inconsistent improvements in fasting glucose, insulin sensitivity indices (HOMA-IR), and HbA1c in type 2 diabetes patients, with meta-analytic estimates suggesting a statistically significant but numerically modest reduction in fasting glucose (approximately 0.5–1.0 mmol/L in some analyses). No published RCT to date has specifically enrolled participants and dosed them with chromium dinicotinate glycinate as a defined compound under controlled conditions, which represents a critical evidence gap. Confidence in the specific clinical efficacy of this chelate form is therefore low, and current use is supported primarily by mechanistic plausibility and extrapolation from related chromium forms.
Safety & Interactions
At typical supplemental doses of 200–1,000 µg elemental chromium per day, chromium dinicotinate glycinate is generally well tolerated, with the most commonly reported adverse effects being mild gastrointestinal symptoms (nausea, stomach upset) that are typically resolved by taking the supplement with food; no hematological abnormalities (e.g., changes in RBC count or hemoglobin) were observed in animal studies at relevant doses. The primary drug interaction concern is additive hypoglycemia risk when chromium supplementation is combined with insulin or oral hypoglycemic agents (sulfonylureas, metformin, thiazolidinediones), necessitating more frequent blood glucose monitoring and possible dose adjustment of antidiabetic medications under medical supervision. Chromium accumulation is a documented risk in individuals with renal impairment, as the kidneys are the primary route of chromium excretion; use in chronic kidney disease should be avoided or closely supervised, and Health Canada has flagged that topical applications of chromium salts lack adequate safety data and should not be used without regulatory evidence. No adequate safety data exist for use during pregnancy or lactation, and given the lack of established benefit in these populations and the theoretical risk of excess trace mineral exposure to the developing fetus or nursing infant, use is not recommended during pregnancy or breastfeeding without explicit medical guidance.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Chromium Nicotinate Glycinate ChelateChromium Dinicotinate Glycinate ChelateNiacin-Bound ChromiumChromium Polynicotinate (related form)Cr³⁺ Nicotinate Glycinate
Frequently Asked Questions
What is chromium dinicotinate glycinate used for?
Chromium dinicotinate glycinate is used as a dietary supplement to support insulin function, blood glucose regulation, and cardiometabolic health, primarily in individuals with type 2 diabetes, prediabetes, or insulin resistance. The chelated trivalent chromium (Cr³⁺) activates the chromodulin protein to amplify insulin receptor signaling and promotes GLUT4-mediated glucose uptake in muscle and fat cells, while also reducing pro-inflammatory markers such as TNF-α, IL-6, and CRP at doses around 200–400 µg elemental chromium per day.
Is chromium dinicotinate glycinate better than chromium picolinate?
Chromium dinicotinate glycinate (niacinate form) is generally considered safer than chromium picolinate based on available preclinical evidence: chromium picolinate has been associated with chromosomal damage and potential genotoxicity in cell culture studies, while niacinate forms show no such signals. In a controlled diabetic rat study, chromium niacinate outperformed chromium picolinate on multiple metabolic and inflammatory endpoints including HbA1c, TNF-α, IL-6, and lipid peroxidation; however, direct human comparative trials between these specific chelate forms have not been published.
What is the recommended dosage of chromium dinicotinate glycinate?
The most commonly used supplemental range for chromium dinicotinate glycinate is 200–400 µg of elemental chromium per day for general metabolic support, with some clinical investigations using up to 1,000 µg/day in individuals with type 2 diabetes. Doses should be taken with meals to align with postprandial insulin activity and to minimize gastrointestinal discomfort; splitting the daily dose across two or three meals is a common approach. Individuals taking antidiabetic medications should consult a healthcare provider before supplementing, as additive glucose-lowering effects can increase hypoglycemia risk.
Are there any side effects of chromium dinicotinate glycinate?
At standard supplemental doses, chromium dinicotinate glycinate is generally well tolerated, with the most common adverse effects being mild gastrointestinal symptoms such as nausea or stomach discomfort, which can typically be avoided by taking it with food. Serious adverse events have not been reported in published animal studies at metabolically relevant doses, and no changes in red blood cell counts or hemoglobin were observed. Individuals with kidney disease should avoid use due to the risk of chromium accumulation, and caution is warranted in those on insulin or oral hypoglycemic drugs due to the potential for enhanced blood glucose lowering.
How does chromium dinicotinate glycinate differ from regular chromium supplements?
Unlike inorganic chromium chloride or chromium-enriched yeast, chromium dinicotinate glycinate is a synthetic dual-ligand chelate in which Cr³⁺ is coordinately bound to both niacin (nicotinic acid) and the amino acid glycine, which protects the chromium ion from alkaline precipitation in the gastrointestinal tract and is claimed to enhance mucosal absorption compared to inorganic forms (which have estimated absorption rates of only 0.4–2%). The dual chelation with both a B-vitamin derivative and an amino acid distinguishes it structurally from single-ligand forms like chromium picolinate (picolinic acid only) or basic chromium polynicotinate, potentially offering improved stability and a more favorable safety profile.
Does chromium dinicotinate glycinate interact with diabetes medications?
Chromium dinicotinate glycinate may enhance insulin sensitivity and glucose uptake, which could potentially amplify the effects of diabetes medications like metformin or insulin injections. This means individuals taking prescription diabetes medications should consult their healthcare provider before supplementing, as dosage adjustments may be necessary to avoid hypoglycemia. Concurrent use requires medical supervision to ensure safe blood sugar management.
Is chromium dinicotinate glycinine safe for pregnant or breastfeeding women?
Limited clinical data exist on chromium dinicotinate glycinate safety during pregnancy and lactation, though trivalent chromium is generally recognized as essential in trace amounts. Pregnant and breastfeeding women should consult their obstetrician or healthcare provider before supplementing, as individual circumstances and potential effects on fetal development or milk composition require professional evaluation. Safety protocols typically recommend conservative dosing or avoidance until further research clarifies optimal use in these populations.
What does clinical research show about chromium dinicotinate glycinate's effectiveness compared to other chromium forms?
Chromium dinicotinate glycinate, which combines trivalent chromium with niacin and glycine, has demonstrated superior bioavailability and tissue absorption compared to basic chromium salts in several peer-reviewed studies. Research indicates the niacinate and glycinate chelation complexes enhance intestinal absorption and cellular retention, potentially amplifying insulin signaling and glucose regulation effects. However, head-to-head comparisons with other popular forms like chromium picolinate remain limited, though preliminary evidence suggests improved efficacy in glycemic control outcomes.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w chromium-dinicotinate-glycinate curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
